CLL

BMS’s Breyanzi Becomes First CAR-T Therapy for Two Types of Leukemia
BioSpace
Fri, 03/15/24 - 11:32 am
Bristol Myers Squibb
CAR-T
CLL
Breyanzi
FDA
JNJ
Carvykti
Eli Lilly’s Jaypirca to dominate CLL BTK inhibitor market by 2032
Biopharma Reporter
Thu, 01/18/24 - 05:04 pm
Eli Lilly
Jaypirca
CLL
Btk inhibitors
Lilly Wins Second Accelerated Approval for Reversible BTK Inhibitor
BioSpace
Mon, 12/4/23 - 09:41 am
Eli Lilly
FDA
Jaypirca
CLL
small lymphocytic leukemia
Btk inhibitors
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
Fierce Pharma
Fri, 05/26/23 - 09:57 am
ASCO 2023
Bristol Myers Squibb
Breyanzi
CAR-T
CLL
SLL
clinical trials
Secura Bio to keep offering blood cancer drug despite negative ODAC vote, OS questions
Endpoints
Thu, 03/23/23 - 08:59 pm
Secura Bio
Copiktra
CLL
small lymphocytic lymphoma
FDA
Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia
Endpoints
Thu, 01/26/23 - 05:09 pm
Bristol Myers Squibb
CAR-T
Breyanzi
CLL
cell therapy
BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial
Endpoints
Thu, 01/19/23 - 08:55 pm
BeiGene
Brukinsa
CLL
FDA
Imbruvica
TG slips out a nasty surprise for investors
EP Vantage
Mon, 01/31/22 - 10:40 am
TG Therapeutics
FDA
CLL
clinical hold
Novartis-backed Penn study proposes boosting CAR-T responses in CLL by waking up 'war weary' T cells
Fierce Biotech
Tue, 08/17/21 - 10:20 am
Novarts
CAR-T
CLL
Kymriah
BeiGene tees up 3-way leukemia competition against J&J-AbbVie, AstraZeneca with Brukinsa win
Fierce Pharma
Mon, 08/2/21 - 10:57 am
BeiGene
Brukinsa
CLL
small lymphocytic lymphoma
clinical trials
In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment
Endpoints
Mon, 06/14/21 - 10:29 am
AstraZeneca
JNJ
AbbVie
clinical trials
CLL
Gazyva
Imbruvica
Venclexta
AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO
BioSpace
Mon, 06/7/21 - 08:41 pm
AstraZeneca
ASCO 2021
breast cancer
CLL
Lynparza
Calquence
TG Therapeutics completes FDA filing for Roche challenger in CLL
Pharmaforum
Tue, 03/30/21 - 11:11 am
TG Therapeutics
FDA
antibodies
CLL
ublituximab-umbralisib
AZ says Calquence is a safer drug than Imbruvica
Pharmaforum
Mon, 01/25/21 - 11:02 am
AstraZeneca
Calquence
Imbruvica
JNJ
AbbVie
CLL
TG Therapeutics set for upsized IPO to develop cancer combination drug
Pharmaforum
Tue, 12/15/20 - 10:33 am
TG Therapeutics
ASH2020
IPOs
CLL
ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice
Fierce Pharma
Sun, 12/6/20 - 07:15 pm
AstraZeneca
BeiGene
JNJ
AbbVie
Calquence
Brukinsa
Imbruvica
CLL
ASH2020
Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab
Pharmaceutical Business Review
Tue, 09/8/20 - 10:41 am
JNJ
Janssen
Europe
Imbruvica
rituximab
CLL
AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise
Endpoints
Wed, 04/22/20 - 10:43 am
AbbVie
JNJ
Imbruvica
FDA
CLL
SLL
Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL
Pharmaceutical Business Review
Mon, 01/20/20 - 10:57 am
Janssen
JNJ
EMA
Imbruvica
CLL
Leukemia rivals try to stay ahead as Merck, Lilly chase
Biopharma Dive
Tue, 12/10/19 - 11:53 pm
Merck
Eli Lilly
AbbVie
JNJ
Imbruvica
ARQ 531
LOXO-305
CLL
ASH2019

Pages